| First Author | Bradley SV | Year | 2007 |
| Journal | Cancer Res | Volume | 67 |
| Issue | 18 | Pages | 8923-31 |
| PubMed ID | 17875735 | Mgi Jnum | J:125099 |
| Mgi Id | MGI:3723545 | Doi | 10.1158/0008-5472.CAN-07-2153 |
| Citation | Bradley SV, et al. (2007) Aberrant huntingtin interacting protein 1 in lymphoid malignancies. Cancer Res 67(18):8923-31 |
| abstractText | Huntingtin interacting protein 1 (HIP1) is an inositol lipid, clathrin, and actin binding protein that is overexpressed in a variety of epithelial malignancies. Here, we report for the first time that HIP1 is elevated in non-Hodgkin's and Hodgkin's lymphomas and that patients with lymphoid malignancies frequently had anti-HIP1 antibodies in their serum. Moreover, p53-deficient mice with B-cell lymphomas were 13 times more likely to have anti-HIP1 antibodies in their serum than control mice. Furthermore, transgenic overexpression of HIP1 was associated with the development of lymphoid neoplasms. The HIP1 protein was induced by activation of the nuclear factor-kappaB pathway, which is frequently activated in lymphoid malignancies. These data identify HIP1 as a new marker of lymphoid malignancies that contributes to the transformation of lymphoid cells in vivo. [Cancer Res 2007;67(18):8923-31]. |
